Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Average Rating of "Hold" from Analysts

Key Points

• Tandem Diabetes Care, Inc. has received a consensus recommendation of "Hold" from fifteen brokerages, with price targets ranging from $14.00 to $45.00.
• CEO John F. Sheridan and CFO Leigh Vosseller significantly increased their ownership by purchasing shares at around $10.23 and $10.89, respectively.
• The company's recent earnings report revealed a loss of ($0.48) per share, missing the consensus estimate, despite a revenue increase of 8.5% year-over-year.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Get Free Report) has earned a consensus recommendation of "Hold" from the fifteen research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and four have assigned a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $22.6667.

Several research firms recently issued reports on TNDM. Stifel Nicolaus cut their price objective on Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Robert W. Baird dropped their price objective on shares of Tandem Diabetes Care from $33.00 to $24.00 and set a "neutral" rating for the company in a report on Thursday, May 1st. UBS Group dropped their price objective on shares of Tandem Diabetes Care from $20.00 to $17.00 and set a "neutral" rating for the company in a report on Thursday, August 7th. Piper Sandler cut shares of Tandem Diabetes Care from an "overweight" rating to a "neutral" rating and dropped their price objective for the company from $30.00 to $14.00 in a report on Thursday, August 7th. Finally, Lake Street Capital cut shares of Tandem Diabetes Care from a "buy" rating to a "hold" rating and dropped their price objective for the company from $75.00 to $12.00 in a report on Monday, August 11th.

Tandem Diabetes Care Trading Up 1.8%

Shares of Tandem Diabetes Care stock traded up $0.19 during trading hours on Thursday, hitting $11.01. The company's stock had a trading volume of 529,164 shares, compared to its average volume of 1,709,615. Tandem Diabetes Care has a twelve month low of $9.98 and a twelve month high of $47.60. The firm has a fifty day moving average of $16.59 and a 200-day moving average of $20.46. The stock has a market cap of $744.22 million, a price-to-earnings ratio of -3.58 and a beta of 1.46. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.88 and a current ratio of 2.44.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The medical device company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.08). The business had revenue of $240.68 million during the quarter, compared to analyst estimates of $238.39 million. Tandem Diabetes Care had a negative net margin of 20.51% and a negative return on equity of 65.40%. The business's revenue for the quarter was up 8.5% on a year-over-year basis. During the same period last year, the company earned ($0.47) EPS. Research analysts forecast that Tandem Diabetes Care will post -1.68 EPS for the current year.

Insider Transactions at Tandem Diabetes Care

In related news, CEO John F. Sheridan acquired 10,000 shares of Tandem Diabetes Care stock in a transaction dated Monday, August 11th. The stock was acquired at an average price of $10.23 per share, for a total transaction of $102,300.00. Following the transaction, the chief executive officer owned 106,327 shares of the company's stock, valued at $1,087,725.21. This represents a 10.38% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Leigh Vosseller purchased 13,720 shares of Tandem Diabetes Care stock in a transaction that occurred on Friday, August 8th. The stock was bought at an average cost of $10.89 per share, with a total value of $149,410.80. Following the completion of the transaction, the chief financial officer owned 25,580 shares of the company's stock, valued at $278,566.20. The trade was a 115.68% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.90% of the company's stock.

Institutional Investors Weigh In On Tandem Diabetes Care

Institutional investors and hedge funds have recently bought and sold shares of the stock. Sessa Capital IM L.P. purchased a new position in Tandem Diabetes Care during the 1st quarter worth approximately $85,574,000. Ophir Asset Management Pty Ltd purchased a new position in Tandem Diabetes Care during the 2nd quarter worth approximately $27,307,000. Hood River Capital Management LLC purchased a new position in Tandem Diabetes Care during the 4th quarter worth approximately $46,035,000. Jacobs Levy Equity Management Inc. grew its stake in Tandem Diabetes Care by 189.0% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,661,013 shares of the medical device company's stock worth $59,830,000 after buying an additional 1,086,337 shares during the last quarter. Finally, Brown Advisory Inc. purchased a new position in Tandem Diabetes Care during the 4th quarter worth approximately $32,889,000.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.